TDF substitution in children and adolescents who were otherwise stable while receiving a first-line nonnucleoside reverse transcriptase inhibitor-based regimen achieved adequate exposure without clinically significant renal or bone adverse events over 96 weeks. While reassuring, these preliminary safety findings may not exclude delayed effects on renal function and bone density.

Extrapulmonary disease accounted for a high proportion of TB in older children and adolescents who presented with symptoms. One-third of patients did not receive DOT and most were cared for by physicians with limited experience in managing TB. Further studies are needed to determine whether these factors influence outcome in pediatric TB.

In endemic areas, dengue infection can cause an acute febrile illness in pregnant women and sepsis-like illness in neonates. Vertical infection did not result in long-term sequelae.

The administration of GPO-VIR S30 fixed-dose combination tablets in fractions or as a whole tablet to children resulted in appropriate NVP exposure and satisfactory virological and immunological benefit. This finding confirms the effectiveness of using a fixed-dose combination as a "transitional option" while waiting for a paediatric fixed-dose combination drug formulation.